Endoscopic scoring indices for assessing disease severity in familial adenomatous polyposis: Systematic review

Abstract

Background and study aims There is limited consensus on the optimal method for measuring disease severity in familial adenomatous polyposis (FAP). We aimed to systematically review the operating properties of existing endoscopic severity indices for FAP.

Methods We searched MEDLINE, EMBASE, and the Cochrane Library from inception to February 2023 to identify randomized controlled trials (RCTs) that utilized endoscopic outcomes or studies that evaluated the operating properties of endoscopic disease severity indices in FAP.

Results A total of 134 studies were included. We evaluated scoring indices and component items of scoring indices, such as polyp count, polyp size, and histology. Partial validation was observed for polyp count and size. The most commonly reported scoring index was the Spigelman classification system, which was used for assessing the severity of duodenal involvement. A single study reported almost perfect interobserver and intra-observer agreement for this system. The InSIGHT polyposis staging system, which was used for assessing colorectal polyp burden, has been partially validated. It showed substantial interobserver reliability; however, the intra-observer reliability was not assessed. Novel criteria for high-risk gastric polyps have been developed and assessed for interobserver reliability. However, these criteria showed a poor level of agreement. Other scoring indices assessing the anal transition zone, duodenal, and colorectal polyps have not undergone validation.

Conclusions There are no fully validated endoscopic disease severity indices for FAP. Development and validation of a reliable and responsive endoscopic disease severity instrument will be informative for clinical care and RCTs of pharmacological therapies for FAP.

Keywords

Endoscopy Upper GI Tract - Precancerous conditions & cancerous lesions (displasia and cancer) stomach - Endoscopy Lower GI Tract - Polyps / adenomas / ... - Colorectal cancer - Endoscopy Small Bowel - Neoplasia

Publication History

Received: 16 January 2024

Accepted after revision: 03 May 2024

Article published online:
18 June 2024

• References

• 1 Jasperson KW, Tuohy TM, Neklason DW. et al. Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044-2058
• 2 Bülow S, Bjork J, Christensen IJ. et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004; 53: 381-386
• 3 Yang J, Gurudu SR, Koptiuch C. et al. American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. Gastrointest Endosc 2020; 91: 963-982
• 4 Monahan KJ, Bradshaw N, Dolwani S. et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut 2020; 69: 411-444
• 5 Church J, Burke C, McGannon E. et al. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 2003; 46: 1175-1181
• 6 Friederich P, de Jong AE, Mathus-Vliegen LM. et al. Risk of developing adenomas and carcinomas in the ileal pouch in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6: 1237-1242
• 7 Moussata D, Napoleon B, Lepilliez V. et al. Endoscopic treatment of severe duodenal polyposis as an alternative to surgery for patients with familial adenomatous polyposis. Gastrointest Endosc 2014; 80: 817-825
• 8 Samadder NJ, Neklason DW, Boucher KM. et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA 2016; 315: 1266-1275
• 9 Yuksekkaya H, Yucel A, Gumus M. et al. Familial adenomatous polyposis; successful use of sirolimus. Am J Gastroenterol 2016; 111: 1040-1041
• 10 West NJ, Clark SK, Phillips RK. et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 2010; 59: 918-925
• 11 Burke CA, Dekker E, Lynch P. et al. Eflornithine plus sulindac for prevention of progression in familial adenomatous polyposis. N Engl J Med 2020; 383: 1028-1039
• 12 Meyskens FL, McLaren CE, Pelot D. et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008; 1: 32-38
• 13 Lynch PM, Burke CA, Phillips R. et al. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut 2016; 65: 286-295
• 14 Vilar-Sanchez E, Burke C, Correa MRC. et al. A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis. Cancer Res 2020; 80: CT236
• 15 Spigelman AD, Williams CB, Talbot IC. et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; 2: 783-785
• 16 Lynch PM, Morris JS, Wen S. et al. A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc 2016; 84: 115-125
• 17 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-W94
• 18 Ma C, MacDonald JK, Nguyen TM. et al. Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis. Aliment Pharmacol Ther 2022; 55: 178-190
• 19 Whiting PF, Rutjes AW, Westwood ME. et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-536
• 20 Page MJ, McKenzie JE, Bossuyt PM. et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 2021; 134: 103-112
• 21 Steinbach G, Lynch PM, Phillips RK. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952
• 22 Lopez-Ceron M, Van Den Broek FJC, Mathus-Vliegen EM. et al. The role of high-resolution endoscopy and narrow-band imaging in the evaluation of upper GI neoplasia in familial adenomatous polyposis. Gastrointestinal Endoscopy 2013; 77: 542-550
• 23 Sample DC, Samadder NJ, Pappas LM. et al. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients. BMC Gastroenterology 2018; 18: 115
• 24 Phillips RK, Wallace MH, Lynch PM. et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50: 857-860
• 25 Anele C, Chauhan J, McGinty P. et al. Attenuated FAP-how should it be defined and what are the clinical outcomes?. Familial Cancer 2017; 16: S70
• 26 Calabrese C, Pratico C, Calafiore A. et al. Eviendep reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosis. World journal of gastroenterology : WJG 2013; 19: 5671-5677
• 27 Monkemuller K, Fry LC, Ebert M. et al. Feasibility of double-balloon enteroscopy-assisted chromoendoscopy of the small bowel in patients with familial adenomatous polyposis. Endoscopy 2007; 39: 52-57
• 28 Park SY, Ryu JK, Park JH. et al. Prevalence of gastric and duodenal polyps and risk factors for duodenal neoplasm in Korean patients with familial adenomatous polyposis. Gut and Liver 2011; 5: 46-51
• 29 Takeuchi Y, Hamada K, Nakahira H. et al. Efficacy and safety of intensive endoscopic intervention (IDP) for multiple duodenal adenomas in patients with familial adenomatous polyposis: A prospective cohort study. Endoscopy 2023; 55: 515-523
• 30 Tanaka K, Sato Y, Ishikawa H. et al. Small Intestinal involvement and genotype-phenotype correlation in familial adenomatous polyposis. Techniq Innovations Gastrointest Endosc 2022; 24: 26-34
• 31 Van Kouwen MCA, Drenth JPH, Van Krieken JHJM. et al. Ability of FDG-PET to detect all cancers in patients with familial adenomatous polyposis, and impact on clinical management. European Journal of Nuclear Medicine and Molecular Imaging 2006; 33: 270-274
• 32 Singh AD, Bhatt A, Joseph A. et al. Natural history of ampullary adenomas in familial adenomatous polyposis: a long-term follow-up study. Gastrointest Endosc 2022; 95: 455-467
• 33 Pyle B, Waller H, Chalmers-Watson T. et al. Including ampullary polyposis staging in the Spigelman classification: Modifying the modified. Familial Cancer 2017; 16: S29-S30
• 34 Yoon JY, Mehta N, Burke CA. et al. The prevalence and significance of jejunal and duodenal bulb polyposis after duodenectomy in familial adenomatous polyposis retrospective cohort study. Ann Surgery 2021; 274: E1071-E1077
• 35 de Oliveira JC, Viana DV, Zanardo C. et al. Genotype-phenotype correlation in 99 familial adenomatous polyposis patients: A prospective prevention protocol. Cancer Medicine 2019; 8: 2114-2122
• 36 Lee C, Kalady M, Burke C. et al. Proposed classification system for ileal pouch adenomas in patients with familial adenomatous polyposis. Dis Colon Rectum 2021; 64: 171
• 37 Mankaney GN, Cruise M, Sarvepalli S. et al. Surveillance for pathology associated with cancer on endoscopy (SPACE): criteria to identify high-risk gastric polyps in familial adenomatous polyposis. Gastrointest Endosc 2020; 92: 755-762
• 38 Richard CS, Berk T, Bapat BV. et al. Sulindac for periampullary polyps in FAP patients. Int J Colorectal Dis 1997; 12: 14-18
• 39 Mallappa S, Samarasinghe M, Neale K. et al. Pre-operative colonoscopy in the management of familial adenomatous polyposis (FAP) patients: We need to do better. Colorectal Dis 2012; 14: 37
• 40 Lynch PM, Morris JS, Ross WA. et al. Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a Web-based tool. Gastrointest Endosc 2013; 77: 455-463
• 41 Bussey HJ, DeCosse JJ, Deschner EE. et al. A randomized trial of ascorbic acid in polyposis coli. Cancer 1982; 50: 1434-1439
• 42 Karstensen JG, Bulow S, Burisch J. et al. Validation of the endoscopic part of the Spigelman classification for evaluating duodenal adenomatosis in familial adenomatous polyposis: a prospective study of interrater and intrarater reliability. Am J Gastroenterology 2022; 117: 343-345
• 43 Groves CJ, Saunders BP, Spigelman AD. et al. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 2002; 50: 636-641
• 44 Latchford AR, Neale KF, Spigelman AD. et al. Features of duodenal cancer in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2009; 7: 659-663
• 45 Thiruvengadam SS, Lopez R, O'Malley M. et al. Spigelman stage IV duodenal polyposis does not precede most duodenal cancer cases in patients with familial adenomatous polyposis. Gastrointest Endosc 2019; 89: 345-354
• 46 Mankaney G, Leone P, Cruise M. et al. Gastric cancer in FAP: a concerning rise in incidence. Fam Cancer 2017; 16: 371-376
• 47 Martin I, Roos VH, Anele C. et al. Gastric adenomas and their management in familial adenomatous polyposis. Endoscopy 2021; 53: 795-801
• 48 Mathus-Vliegen EM, Boparai KS, Dekker E. et al. Progression of duodenal adenomatosis in familial adenomatous polyposis: due to ageing of subjects and advances in technology. Fam Cancer 2011; 10: 491-499